NPT-088 / Proclara Biosci - LARVOL DELTA

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease. (PubMed, J Prev Alzheimers Dis) - "At endpoint NPT088 was generally safe and well-tolerated with the most prominent finding being infusion reactions in a minority of patients. No effect of NPT088 on brain plaques, tau aggregates or Alzheimer's disease symptoms was observed."

Clinical • Journal • Alzheimer's Disease • CNS Disorders

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease (clinicaltrials.gov) - P1; N=83; Completed; Sponsor: Proclara Biosciences, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion